February 9, 2017 / 11:48 AM / 6 months ago

BRIEF-Regeneron posts Q4 adj. profit $3.04/shr

Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron reports fourth quarter and full year 2016 financial and operating results

* Regeneron Pharmaceuticals Inc - Q4 2016 eylea global net sales increased 17 pct to $1.35 billion versus Q4 2015

* Regeneron Pharmaceuticals Inc - in Q4 of 2016, global net sales of praluent were $41 million, compared to $7 million in Q4 of 2015

* Says net product sales were $863 million in Q4, compared to $750 million

* Regeneron Pharmaceuticals Inc - total revenues increased by 12 pct to $1.227 billion in Q4 of 2016

* Regeneron Pharmaceuticals Inc - sees 2017 Sanofi reimbursement of Regeneron commercialization-related expenses of $400 million - $450 million

* Regeneron Pharmaceuticals Inc qtrly non-GAAP net income per share $3.04

* Qtrly GAAP net income per share $2.19

* Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S

* Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product sales in 2017

* Regeneron Pharmaceuticals Inc - "also studying dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis"

* Regeneron - dupixent may have potential to help additional patients with serious allergic diseases, Phase 3 data in adult asthma patients expected later this year

* Regeneron Pharmaceuticals Inc - pre-approval inspection for dupixent has been scheduled for Q1 of 2017

* Regeneron Pharma - in Jan, FDA extended review period for supplemental biologics license application (SBLA) for a monthly dosing regimen of praluent

* Regeneron - FDA determined that Regeneron's and Sanofi's responses to information requested by FDA during its review of SBLA was a major amendment

* Regeneron - new target action date for supplemental biologics license application (SBLA) for a monthly dosing regimen of praluent is April 24, 2017

* Regeneron Pharmaceuticals Inc - Q4 2016 eylea (aflibercept) injection U.S. net sales increased 15 pct to $858 million versus Q4 2015

* Regeneron Pharmaceuticals Inc -sees FY 2017 capital expenditures $375 million - $450 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below